

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

1 July 2011

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(17 pages by email)

Dear Madam

CEO PRESENTATION AT BIO2011 IN WASHINGTON DC

Biotron Limited's Managing Director, Dr Michelle Miller, has presented the attached update of the Company's activities to an international audience at the annual international biotechnology industry convention, BIO2011, in Washington DC.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities. A key feature of BIO is the Business Forum offers which provides a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities in one-on-one meetings and company presentations.


In addition, Dr Miller has given briefings to US institutional investors and pharmaceutical company representatives as part of activities surrounding BIO2011, including presenting at the Australian Life Sciences Investment Showcase in New York.

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

For further information please contact Dr Michelle Miller, Managing Director, on (61-2) 9805 0488.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn6096

Biotron

BIOTRON LIMITED

ASX:BIT

BIO2011

Michelle Miller

CEO & Managing Director

Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Biotron Ltd Overview

- Established in 1999 as a spin-out from the Australian National University, Canberra; Currently based in Sydney, Australia
- IPO on ASX in Jan 2001 (ASX:BIT)
- Focus on developing novel small molecule antiviral drugs
 - Hep C, HIV, Dengue and others
- Key highlights
 - Successful implementation of clinical trials for the Hep C and HIV programs
 - Successful capital raisings in challenging market conditions
 - A\$2.7m in 2010; A\$2.4m in 1Q2011
 - A\$23m since foundation

The Biotron logo is located in the bottom right corner of the slide. It features the word "Biotron" in a stylized, italicized, blue font. The text is enclosed within a thin, light blue rectangular border that has rounded corners and a slight 3D effect.

Capital Structure & Financials

Shares on issue	148 m
Listed options	108 m (exp Dec 2011)
Current S/P	A\$0.10
52 wk high/ low	A\$0.15/ 0.051
Market cap	A\$15 m
Cash at 31 March 11	A\$1.3m*

**excludes proceeds of share placement in April 2011, raising A\$1.7m*





The Biotron logo is located in the bottom right corner of the slide. It features the word "Biotron" in a stylized, italicized blue font, enclosed within a white rounded rectangular border.

Core Technology

- Identification of new class of viral proteins called viroporins
 - Small hydrophobic proteins with ion channel activity
 - Key roles in production and release of infectious virus
 - Present in influenza (M2), HIV (Vpu), Hep C (p7), Dengue (M) , SARS (E) and others
- Ongoing need for new drugs to overcome viral resistance; patients are treated with cocktails of antiviral drugs
- Designed library of new drugs to target these viral targets
 - >350 compounds designed , synthesised and screened
- Developed proprietary bacterial screening assays for HIV-1 Vpu, HCV p7, Coronavirus E, Influenza M2, and Dengue M protein.
- Generating first-in-class drugs to treat these diseases
 - Initial focus on HIV and Hep C

Pipeline

- Two clinical phase programs:
 - Hepatitis C virus (BIT225) and HIV
- Current status of pipeline:

Project	Target	Discovery	Preclinical	Clinical Trials		
				Phase I	Ph Ib/IIa	Ph II
Hep C	p7					
HIV	Vpu					
Dengue	M protein					
+ other targets						

Hepatitis C Virus – The Silent Killer

- 170 m people infected worldwide; 4 m patients in US (2.7m chronic infection)
- Majority remain asymptomatic for decades before developing cirrhosis or liver cancer
- US surgeon general considers hepatitis C is one of the most significant public health threats facing US.
 - 40 – 50% of liver transplants are due to HCV
- Standard of care is interferon and ribavirin
 - not direct acting on virus
 - Up to 50% patients don't respond to current treatment
 - Significant side effect profile
 - Documented need for new, safer drugs


The Biotron logo is located in the bottom right corner of the slide. It features the word "Biotron" in a stylized, italicized blue font, enclosed within a white rounded rectangular border.

Hep C – An Expanding Market

Worldwide market ~US\$2.8 billion;
predicted to expand to >US\$10 billion
as new, safer drugs enter the market.

Only small percentage currently receive
treatment.

USA and Europe represent major
markets but other, larger markets are
emerging.



Copyright © 2006 Nature Publishing Group
Nature Reviews | Drug Discovery

Smith Nature Reviews Drug Discovery 5, 715–716 (September 2006)

Biotron

Hep C Lead Product – BIT225

- BIT225 is a new investigational oral small molecule drug in development for treating Hep C infection
- Completed two clinical trials:
 - **Phase Ia** – 48 patient, single dose safety study in healthy volunteers; Status - completed
 - **Phase Ib** - 18 patient, 7-day multiple dose study in patients with Hepatitis C Virus infection; Status - completed
- **Phase IIa** – 24 patient, 28-day multiple dose study in patients with Hepatitis C infection (genotype 1)
 - Combination with pegylated Interferon and Ribavirin.
 - Status - trial commenced Sept 2010 and due to complete recruitment mid 2011.

BIT225 Clinical Information

- p7 critical role in production of infectious HCV in infected cells
- Phase Ia results demonstrated BIT225 well-tolerated at doses up to 600mg with no dose-limiting toxicities
- Phase Ib results demonstrated 200 mg BIT225 significantly reduced HCV levels compared to placebo ($p=0.0002$)
 - 3 of the 6 subjects receiving 200 mg of BIT225 had significant reductions in viral loads.
- Phase IIa – 24 subjects (HCV+, genotype 1) commencing standard of care (SOC) to receive 200 or 400 mg BIT225 (or placebo) twice daily for 28 days

Rationale for Phase II Hep C Trial

- Future Hep C therapies expected to be a cocktail of drugs
 - In short-term new drugs to be used with current approved drugs interferon (IFN) and ribavirin
 - Industry focus on developing new, specific direct-acting antiviral drugs to use in combination
 - P7-inhibitors e.g. BIT225 are potential new additions to this mix
 - Biotron is well positioned to partner with either current OR future therapies as synergistic with BOTH
- BIT225 expected to have significantly higher potency in combination with interferon and ribavirin on basis of preclinical data
- Phase II trial is a combination study of BIT225 with interferon and ribavirin

The Biotron logo is located in the bottom right corner of the slide. It features the word "Biotron" in a stylized, italicized blue font, enclosed within a white rounded rectangular border.

Hep C Phase II Combination Trial

Ph II Trial Period			<i>Trial design</i>	
0	2	4	Weeks	44 wks
8 pts	Placebo		Interferon + Ribavirin	
8 pts	BIT225 (200 mg) + IFN/rib		Interferon + Ribavirin	
8 pts	BIT225 (400 mg) + IFN/rib		Interferon + Ribavirin	





- Pts randomly assigned to receive either placebo or BIT225 twice daily for 28 days commencement of standard combination therapy for Hep C (IFN/ribavirin)
- Patients continue after 28 days just on IFN/ribavirin as part of their standard treatment (external to Phase II trial)
- 24 patients, genotype 1
- Trial commenced Sept 2010 in Thailand
- Expect to complete recruitment mid-2011

Biotron's HIV Clinical Program

- First-in-class new anti-HIV drug targeting HIV-Vpu protein
 - New mode of action – inhibits budding of virus from infected cells
 - Targets HIV in viral reservoirs *in vivo*
 - ***Reservoirs are last of the holy grail in HIV***
 - ***No existing drugs target this source of HIV in the body***
 - ***Eradication of reservoirs is essential for “cure” of HIV***
- Completed Phase I safety trial in healthy volunteers
- Phase Ib – 24 subject randomized trial in HIV+ patients anticipated to commence in 3Q2011
- Trial designed to demonstrate proof-of-concept
 - i.e. can reduce HIV loads in HIV-infected reservoir cells

The Biotron logo is located in the bottom right corner of the slide. It consists of the word "Biotron" in a stylized, italicized, blue font, enclosed within a thin, light blue rectangular border.

Human Reservoirs cells infected with HIV – Untreated (A) and Treated with BIT225 (B)



Biotron

Investment Summary

- Developing first-in-class antiviral drugs
- Successfully completed two human trials of BIT225
 - Good safety and promising efficacy results
- Pivotal Phase IIa Hep C trial results anticipated early 3Q 2011
- Potential to combine BIT225 with current or next generation Hep C drugs
- Biotron has back-up drugs and proprietary assays to facilitate development of 2nd generation drugs
- Novel approach to treating HIV reservoirs anticipated to commence Phase Ib in 3Q 2011
- Additional early stage drug discovery projects for Dengue and others
- Strong patent protection – 5 patent families filed worldwide
- Seeking w/w partnership for further development

The Biotron logo is located in the bottom right corner of the slide. It features the word "Biotron" in a stylized, italicized blue font, enclosed within a white rounded rectangular border.



Michelle Miller

Managing Director

+61 2 9805 0488

+61 412 313329

mmiller@biotron.com.au

www.biotron.com.au